Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

LIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

REVENUES:

Sales $489,664 $428,729 $1,408,603 $1,287,802

Other revenues 8,818 9,692 25,813 34,865

498,482 438,421 1,434,416 1,322,667

COSTS AND EXPENSES:

Cost of sales 121,477 82,258 312,711 251,970

Research and development 88,325 93,527 250,169 274,078

Selling, general and

administrative 222,948 186,456 631,832 527,962

Settlement reserve 7,450 369,000 7,450 425,000

Restructuring charges 1,497 - 6,973 -

In-process research and

development - - 10,000 -

441,697 731,241 1,219,135 1,479,010

INCOME (LOSS) FROM

OPERATIONS 56,785 (292,820) 215,281 (156,343)

OTHER INCOME (EXPENSE):

Interest income 4,002 8,868 15,515 23,485

Interest expense (8,831) (5,660) (25,697) (15,272)

Gain on extinguishment of

debt - 5,319 - 5,319

Gain on sale of investment - - - 5,791

Other income (expense), net (2,284) 2,493 1,488 3,747

(7,113) 11,020 (8,694) 23,070

INCOME (LOSS) BEFORE INCOME

TAXES
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... (PRWEB) June 18, 2013 Demanding industrial ... Lenses engineered of synthetic Sapphire and Glass Ball Lenses, ... from Swiss Jewel Company , of Philadelphia , ... expanding and collimating the light beams without the need ... clarity and natural durability (9 mohs) make it the ...
(Date:6/18/2013)... 2013 RegeneCure announced today ... AMCA Guided Bone Regeneration (GBR) Dental Membrane as a bone ... common problem encountered when patients have a tooth replaced with ... to house the implant. Consequently there is often a need ... natural bone regenerates. The bone substitute material, in turn, needs ...
(Date:6/18/2013)... ALBANY, N.Y. , June 18, 2013 /PRNewswire/ ... that its Burlington, Mass. , ... U.S. Drug Enforcement Administration (DEA) registration to handle ... represents the DEA,s acknowledgement of Burlington,s ... inventory control and documentation. (Logo: ...
(Date:6/18/2013)... Canada (PRWEB) June 18, 2013 ... oversight of pharmaceutical advertising and promotion, and review ... Viewers will learn how to apply these principles ... examples:, ,     The fundamentals on FDA ... and promotional labeling ,     Assessing traditional and ...
Breaking Biology Technology:Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2
... TROMS0, Norway and SEOUL, Korea, June 19 ... KAEL-GemVax,today announced the signing of a collaborative agreement to ... for the treatment of,cancer. , ... CEO Jay,Sangjae Kim, "We are delighted to announce this ...
... research from Cincinnati Children,s Hospital Medical Center highlights the critical ... embryonic development on formation of a normal heart and skull. ... Proceedings of the National Academy of Sciences , a ... the gene/protein SHP2 interferes with the normal developmental activity of ...
... Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biopharmaceutical ... HIV-1 (Human Immunodeficiency Virus), and other infectious agents, announced ... cooperative arrangement with Cook County Board President Todd H. ... County Health and Hospitals Systems Board ("Health System"); and ...
Cached Biology Technology:Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy 2Scientists identify gene vital to early embryonic cells forming a normal heart and skull 2GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 2GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 3GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 4GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 5
(Date:6/18/2013)... chemical modification of DNA and this modification can ... sequence. Until now, scientists believed that this epigenetic ... Today, a team of researchers from the University ... Louis-Jeantet Professor at the Faculty of Medicine, reveals ... that DNA methylation may play both a passive ...
(Date:6/17/2013)... a new virus in patients with severe brain infections ... the virus is responsible for the symptoms of disease. ... 28 out of 644 patients with severe brain infections ... in any of the 122 patients with non-infectious brain ... and central nervous system are often fatal and patients ...
(Date:6/17/2013)... foundations with more modern elements. Using this same approachbut ... Dietrich School of Arts and Sciences have designed a ... storage, and gas transport more efficient and at a ... issue of the Journal of the American Chemical ... builds upon Pitt Associate Professor of Chemistry Nathaniel Rosi,s ...
Breaking Biology News(10 mins):The secret of DNA methylation 2New virus isolated from patients with severe brain infections 2New virus isolated from patients with severe brain infections 3'Chemical architects' build materials with potential applications in drug delivery and gas storage 2
... 12 collaborating institutions have been awarded $24 million in ... for Environmental Implications of Nanotechnology (UC CEIN), which will ... The center, to be housed ... campus, will explore the impact of nanomaterials on life ...
... DURHAM, NC--The National Science Foundation (NSF) and the Environmental ... the Center for Environmental Implications of NanoTechnology (CEINT) to ... Nanoparticles are as much as a million times smaller ... properties compared with larger objects made from the same ...
... University of North Carolina at Chapel Hill School of Medicine ... insulin, the hormone used to treat diabetes. The ... a cure for the millions of people affected by the ... into pluripotent stem cells, or cells that can give rise ...
Cached Biology News:UCLA, partners establish new center on environmental effects of nanotechnology 2UCLA, partners establish new center on environmental effects of nanotechnology 3UCLA, partners establish new center on environmental effects of nanotechnology 4Duke to lead new NSF, EPA center to study the environmental implications of nanotechnology 2Duke to lead new NSF, EPA center to study the environmental implications of nanotechnology 3UNC scientists turn human skin cells into insulin-producing cells 2
... new Vivaspin 2 bridges the gap between ... concentrators. This device combines the speed of ... surface and membrane area for superior recoveries ... a choice of PES, Cellulose Triacetate membranes, ...
... II) is involved in translation initiation. PHAS-II ... proteins bind to eIF-4E, the mRNA cap-binding ... in vitro and in cells. Phosphorylation in ... complexes. This allows eIF-4E to bind to ...
Goat polyclonal to Lipocalin 2...
... Vesicular Monoamine Transporter 2 (VMAT2). An antibody ... a major band at ~55 kDa in ... and not in wild type cells (2). ... molecular weight, were also detected and remain ...
Biology Products: